Sickle cell disease in Black children: what parents should know about newborn screening, pain crises, and the 2023 gene therapies.

Sickle cell disease affects about 100,000 Americans, and it occurs in roughly 1 of every 365 Black or African American births in the United States, according to the CDC sickle cell surveillance page. More than 90 percent of the people living with the disease in this country are Black. If you are a parent or a caregiver, the three things that will shape your child's first decade with this condition are the newborn screening result, how your family handles pain crises, and whether you reach a pediatric hematologist who actually treats sickle cell every week. This guide walks through each one, and closes with what the December 2023 FDA gene-therapy approvals mean for a family deciding what to do next. For a plain definition of the disease itself, see our glossary entry on sickle cell disease.

All 50 states and the District of Columbia screen every baby for sickle cell disease as part of the standard heel-prick blood test in the first days after birth. That part is uniform. What is not uniform is what happens after a positive result. Families on Medicaid, families in rural counties, and families in states without a nearby pediatric hematology center often wait weeks for a confirmatory test and a first specialist visit, when the clinical recommendation is days. The NHLBI 2014 evidence-based report on sickle cell disease management puts early specialist contact and family education at the center of the first year of care. Ask the hospital that delivered your baby for the name of the pediatric hematology clinic they refer to, and call that clinic yourself if you have not heard from them within two weeks of the screening result.

A vaso-occlusive crisis is when sickled red cells block small blood vessels, and it causes the severe pain that children and adults with this disease describe as unlike anything else. Go to the emergency department when pain is not controlled by the home plan your hematologist gave you, when fever crosses 101.3 degrees Fahrenheit, when breathing changes, when there is chest pain, or when a child is unusually sleepy or will not drink. At triage, tell the nurse your child has sickle cell disease and is in a pain crisis, and ask for pain medication to be started within 60 minutes of arrival, which is the target set by the American Society of Hematology sickle cell guidelines. Bring your child's individualized pain plan on paper. Bring the hematologist's phone number. These are the two documents that change how fast an ER moves.

Children with sickle cell disease have impaired spleen function from infancy, which leaves them vulnerable to infections from encapsulated bacteria, especially Streptococcus pneumoniae. Twice-daily oral penicillin V from about two months of age through age five reduces the risk of serious bloodstream infection, a finding that dates to the 1986 PROPS trial and is reflected in the NHLBI 2014 evidence-based management report. Keep your child on the full pediatric vaccine schedule, including the pneumococcal and meningococcal series your hematologist will add. If your child develops a fever above 101.3, call the hematology team the same day. Delayed antibiotics in a febrile child with sickle cell disease is a named clinical error families still see in ERs that do not treat the disease regularly.

Hydroxyurea is a daily oral medicine that raises fetal hemoglobin levels and reduces the frequency of pain crises, acute chest syndrome, and hospital stays. The NHLBI 2014 expert panel report recommends offering hydroxyurea to every infant with sickle cell anemia starting at about 9 months of age, regardless of clinical severity, based on the BABY HUG trial data. Blood counts are monitored every few weeks when treatment starts and at longer intervals once the dose is stable. Ask your hematologist which dose your child is on, how it was chosen, and what fetal-hemoglobin level they are targeting. If the clinic you are at is not offering hydroxyurea to a child approaching the first birthday, that is a sign to ask why in writing, or to seek a second opinion at a sickle cell center of excellence.

On December 8, 2023, the FDA approved two gene therapies for people with sickle cell disease aged 12 and older: Casgevy (exagamglogene autotemcel), developed by Vertex Pharmaceuticals and CRISPR Therapeutics, and Lyfgenia (lovotibeglogene autotemcel), developed by bluebird bio. Casgevy is the first CRISPR-based medicine approved for any condition in the United States. Both therapies edit or add to the patient's own blood stem cells outside the body, then infuse them back after a round of high-dose chemotherapy called myeloablative busulfan conditioning, which wipes the existing bone marrow to make room for the edited cells. The pivotal Casgevy trial reported that 29 of 30 evaluable patients with severe sickle cell disease were free from vaso-occlusive crises for at least 12 consecutive months after treatment, a 97 percent response rate with a 95 percent confidence interval of 83 to 100 (Frangoul et al., NEJM 2024, PMID 38661449).

The clinical result is real. The access reality is narrow. Casgevy's list price is 2.2 million dollars per treatment course; Lyfgenia's is 3.1 million. The 2023 Institute for Clinical and Economic Review Final Evidence Report set a cost-effectiveness range of 1.35 to 2.05 million dollars per course (ICER, Gene Therapies for Sickle Cell Disease, 2023). Beyond price, the therapy itself requires a bone-marrow harvest, weeks of inpatient myeloablative chemotherapy, and a credentialed authorized treatment center capable of performing autologous hematopoietic stem cell transplant. Only a fraction of the 100,000 Americans with sickle cell disease currently lives within practical travel distance of such a center. Every active CRISPR sickle cell trial in the US ClinicalTrials.gov registry is still ex-vivo, meaning cells are edited outside the body, and no in-vivo approach that would avoid the chemotherapy step is yet in human trials for this disease.

Take these questions to your child's next appointment. Write the answers down. Bring the paper back. First: Is my child on hydroxyurea, and if not, why not? Second: What is our written fever plan, and what is the phone number I call at 2 a.m.? Third: What is our individualized pain plan, and is it on file at our nearest ER? Fourth: Are we near an authorized treatment center that offers Casgevy or Lyfgenia, and what are the age, severity, and insurance criteria to be considered later? To find a pediatric hematologist who specializes in sickle cell disease, search the Sickle Cell Disease Association of America member organization directory, or ask your child's pediatrician for the nearest sickle cell center of excellence.